The myopia and presbyopia treatment market size has grown strongly in recent years. It will grow from $21.04 billion in 2024 to $22.7 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing prevalence of myopia and presbyopia, awareness and education initiatives, shift in lifestyles and screen time, consumer preference for non-surgical treatments, economic growth and healthcare spending, clinical research and development, accessibility to eyecare services.
The myopia and presbyopia treatment market size is expected to see strong growth in the next few years. It will grow to $31.43 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to emergence of gene therapies for eye disorders, focus on vision correction for lifestyle enhancement, growing adoption of orthokeratology, cultural factors impacting eyecare practices, shift towards preventive eyecare. Major trends in the forecast period include telemedicine for vision care, pharmaceutical interventions, customized contact lenses, myopia control devices, advanced intraocular lenses (IoLS), refractive surgery for presbyopia, and lens implant technologies.
The projected rise in the geriatric population, specifically individuals aged 65 and above, is anticipated to propel the growth of the myopia and presbyopia treatment market. This demographic segment, due to age-related vulnerabilities and lowered immunity, experiences heightened risks of eye-related ailments, including myopia and presbyopia. Treatments targeting these conditions often involve thorough examination of the visual and microscopic elements of the eye, aiding in the identification and management of various eye-related illnesses prevalent among the elderly. According to the World Health Organization's October 2022 report, by 2030, one in six individuals globally will be 60 or older, and by 2050, the worldwide population aged 60 or above is estimated to reach 2.1 billion, indicating a substantial surge in demand for treatments addressing age-related vision issues.
The escalating incidence of vision impairment is poised to drive growth in the myopia and presbyopia treatment market. Vision impairment, characterized by reduced visual interpretative abilities, poses challenges in perceiving and comprehending the surrounding environment. This trend is anticipated to spur the development of treatments, encouraging heightened awareness, innovation, and investments in the field. Notably, a report from the Centers for Disease Control and Prevention in August 2023 highlights a projected increase in vision impairment cases to 8.96 million by 2050 in the United States. Factors contributing to this rise include the prevalence of chronic diseases like diabetes and an aging population. Moreover, approximately 6.8% of children under 18 in the U.S. have been diagnosed with eye and vision issues, emphasizing the need for effective solutions catering to various age groups experiencing visual challenges.
Technologically advanced solutions are a key trend gaining traction in the myopia and presbyopia treatment market. Major companies are focusing on developing innovative solutions to maintain their competitive edge. For instance, in September 2024, Entod Pharmaceuticals, an India-based manufacturing company, launched PresVu Eye Drops, marking the first eye drop in India specifically formulated for treating presbyopia, a common age-related vision condition that typically affects individuals over 40 years old. Approved by the Drug Controller General of India (DCGI), PresVu is designed to reduce the reliance on reading glasses while providing lubrication to the eyes. These eye drops employ advanced dynamic buffer technology, ensuring consistent efficacy and safety for prolonged use.
Companies in the myopia and presbyopia treatment sector are innovating products, such as myopia-combating sun spectacle lenses, to broaden their customer base and drive revenue growth. Notably, in May 2023, HOYA launched MiYOSMART sun spectacle lenses, designed to mitigate myopia progression in children. These lenses, incorporating DIMS Technology, offer specialized options like MiYOSMART Chameleon and MiYOSMART Sunbird, aiming to slow myopia progression while providing sunlight protection. This technology, developed in collaboration with the Hong Kong Polytechnic University, introduces defocus elements to regulate myopia progression during outdoor activities. The market's emphasis on innovation aligns with emerging evidence supporting outdoor time as a preventive measure against myopia, emphasizing the significance of encouraging outdoor engagements for myopic children.
In January 2024, Eyenovia Inc., a US-based ophthalmic pharmaceutical technology company, acquired the development and commercialization rights for MicroPine from Bausch + Lomb Ireland Limited for an undisclosed amount. The purpose of this acquisition is to accelerate the commercialization of advanced ophthalmic products, specifically aimed at treating pediatric progressive myopia, thus enhancing their late-stage pipeline and addressing a significant unmet medical need in the U.S. and Canada. Bausch + Lomb Ireland Limited is an Ireland-based eye health company involved in the development of MicroPine for myopia treatment.
Major companies operating in the myopia and presbyopia treatment market are ALCON Inc., Bausch & Lomb Incorporated, Carl Zeiss AG, Essilor Ltd., Hagg Striet UK Ltd., Johnson & Johnson Vision Inc., Nidek Corporation, Topcon Corporation, Zimmer Ophthalmic Systems AG, AbbVie Inc., Orasis Pharmaceuticals Ltd., Regeneron Pharmaceuticals Inc., Sydnexis Inc., The Cooper Companies Inc., Staar Surgical Co., Eyenovia Inc., Allergan PLC, Hoya Corporation, Novartis AG, Menicon Co. Ltd., CooperVision Inc., Visioneering Technologies Inc., AcuFocus Inc., Ocular Therapeutix Inc., SightGlass Vision Inc., Presbia PLC, Ophthotech Corporation, OphthaliX Inc., LensGen Inc., Lightico Ltd., RxSight Inc., Perfect Lens LLC.
North America was the largest region in the myopia and presbyopia treatment market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myopia and presbyopia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myopia and presbyopia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Myopia and presbyopia treatment encompasses procedures or therapies aimed at rectifying and enhancing vision affected by myopia and presbyopia, both in adults and children. The primary objective revolves around diagnosing underlying conditions, mitigating injury risks, alleviating ocular symptoms, and early detection of these eye conditions.
The main focus of myopia and presbyopia treatment is on two specific eye conditions such as myopia and presbyopia. Myopia involves visual images focusing in front of the retina, resulting in reduced clarity when viewing distant objects. Treatments for myopia cater to both adults and children, encompassing corrective measures, surgical interventions, and pharmaceutical approaches. On the other hand, presbyopia treatment methods comprise prescription lenses, contact lenses, intraocular lenses, and refractive surgeries, specifically targeting presbyopia-related visual impairments.
The myopia and presbyopia treatment market research report is one of a series of new reports that provides myopia and presbyopia treatment market statistics, including myopia and presbyopia treatment industry global market size, regional shares, competitors with a myopia and presbyopia treatment market share, detailed myopia and presbyopia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the myopia and presbyopia treatment industry. This myopia and presbyopia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The myopia and presbyopia treatment market includes revenues earned by entities by performing refractive surgery, lens implants, bifocal surgery services and providing eye sight management treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The myopia and presbyopia treatment market size is expected to see strong growth in the next few years. It will grow to $31.43 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to emergence of gene therapies for eye disorders, focus on vision correction for lifestyle enhancement, growing adoption of orthokeratology, cultural factors impacting eyecare practices, shift towards preventive eyecare. Major trends in the forecast period include telemedicine for vision care, pharmaceutical interventions, customized contact lenses, myopia control devices, advanced intraocular lenses (IoLS), refractive surgery for presbyopia, and lens implant technologies.
The projected rise in the geriatric population, specifically individuals aged 65 and above, is anticipated to propel the growth of the myopia and presbyopia treatment market. This demographic segment, due to age-related vulnerabilities and lowered immunity, experiences heightened risks of eye-related ailments, including myopia and presbyopia. Treatments targeting these conditions often involve thorough examination of the visual and microscopic elements of the eye, aiding in the identification and management of various eye-related illnesses prevalent among the elderly. According to the World Health Organization's October 2022 report, by 2030, one in six individuals globally will be 60 or older, and by 2050, the worldwide population aged 60 or above is estimated to reach 2.1 billion, indicating a substantial surge in demand for treatments addressing age-related vision issues.
The escalating incidence of vision impairment is poised to drive growth in the myopia and presbyopia treatment market. Vision impairment, characterized by reduced visual interpretative abilities, poses challenges in perceiving and comprehending the surrounding environment. This trend is anticipated to spur the development of treatments, encouraging heightened awareness, innovation, and investments in the field. Notably, a report from the Centers for Disease Control and Prevention in August 2023 highlights a projected increase in vision impairment cases to 8.96 million by 2050 in the United States. Factors contributing to this rise include the prevalence of chronic diseases like diabetes and an aging population. Moreover, approximately 6.8% of children under 18 in the U.S. have been diagnosed with eye and vision issues, emphasizing the need for effective solutions catering to various age groups experiencing visual challenges.
Technologically advanced solutions are a key trend gaining traction in the myopia and presbyopia treatment market. Major companies are focusing on developing innovative solutions to maintain their competitive edge. For instance, in September 2024, Entod Pharmaceuticals, an India-based manufacturing company, launched PresVu Eye Drops, marking the first eye drop in India specifically formulated for treating presbyopia, a common age-related vision condition that typically affects individuals over 40 years old. Approved by the Drug Controller General of India (DCGI), PresVu is designed to reduce the reliance on reading glasses while providing lubrication to the eyes. These eye drops employ advanced dynamic buffer technology, ensuring consistent efficacy and safety for prolonged use.
Companies in the myopia and presbyopia treatment sector are innovating products, such as myopia-combating sun spectacle lenses, to broaden their customer base and drive revenue growth. Notably, in May 2023, HOYA launched MiYOSMART sun spectacle lenses, designed to mitigate myopia progression in children. These lenses, incorporating DIMS Technology, offer specialized options like MiYOSMART Chameleon and MiYOSMART Sunbird, aiming to slow myopia progression while providing sunlight protection. This technology, developed in collaboration with the Hong Kong Polytechnic University, introduces defocus elements to regulate myopia progression during outdoor activities. The market's emphasis on innovation aligns with emerging evidence supporting outdoor time as a preventive measure against myopia, emphasizing the significance of encouraging outdoor engagements for myopic children.
In January 2024, Eyenovia Inc., a US-based ophthalmic pharmaceutical technology company, acquired the development and commercialization rights for MicroPine from Bausch + Lomb Ireland Limited for an undisclosed amount. The purpose of this acquisition is to accelerate the commercialization of advanced ophthalmic products, specifically aimed at treating pediatric progressive myopia, thus enhancing their late-stage pipeline and addressing a significant unmet medical need in the U.S. and Canada. Bausch + Lomb Ireland Limited is an Ireland-based eye health company involved in the development of MicroPine for myopia treatment.
Major companies operating in the myopia and presbyopia treatment market are ALCON Inc., Bausch & Lomb Incorporated, Carl Zeiss AG, Essilor Ltd., Hagg Striet UK Ltd., Johnson & Johnson Vision Inc., Nidek Corporation, Topcon Corporation, Zimmer Ophthalmic Systems AG, AbbVie Inc., Orasis Pharmaceuticals Ltd., Regeneron Pharmaceuticals Inc., Sydnexis Inc., The Cooper Companies Inc., Staar Surgical Co., Eyenovia Inc., Allergan PLC, Hoya Corporation, Novartis AG, Menicon Co. Ltd., CooperVision Inc., Visioneering Technologies Inc., AcuFocus Inc., Ocular Therapeutix Inc., SightGlass Vision Inc., Presbia PLC, Ophthotech Corporation, OphthaliX Inc., LensGen Inc., Lightico Ltd., RxSight Inc., Perfect Lens LLC.
North America was the largest region in the myopia and presbyopia treatment market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myopia and presbyopia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myopia and presbyopia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Myopia and presbyopia treatment encompasses procedures or therapies aimed at rectifying and enhancing vision affected by myopia and presbyopia, both in adults and children. The primary objective revolves around diagnosing underlying conditions, mitigating injury risks, alleviating ocular symptoms, and early detection of these eye conditions.
The main focus of myopia and presbyopia treatment is on two specific eye conditions such as myopia and presbyopia. Myopia involves visual images focusing in front of the retina, resulting in reduced clarity when viewing distant objects. Treatments for myopia cater to both adults and children, encompassing corrective measures, surgical interventions, and pharmaceutical approaches. On the other hand, presbyopia treatment methods comprise prescription lenses, contact lenses, intraocular lenses, and refractive surgeries, specifically targeting presbyopia-related visual impairments.
The myopia and presbyopia treatment market research report is one of a series of new reports that provides myopia and presbyopia treatment market statistics, including myopia and presbyopia treatment industry global market size, regional shares, competitors with a myopia and presbyopia treatment market share, detailed myopia and presbyopia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the myopia and presbyopia treatment industry. This myopia and presbyopia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The myopia and presbyopia treatment market includes revenues earned by entities by performing refractive surgery, lens implants, bifocal surgery services and providing eye sight management treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Myopia and Presbyopia Treatment Market Characteristics3. Myopia and Presbyopia Treatment Market Trends and Strategies4. Myopia and Presbyopia Treatment Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Myopia and Presbyopia Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Myopia and Presbyopia Treatment Market34. Recent Developments in the Myopia and Presbyopia Treatment Market
5. Global Myopia and Presbyopia Treatment Growth Analysis and Strategic Analysis Framework
6. Myopia and Presbyopia Treatment Market Segmentation
7. Myopia and Presbyopia Treatment Market Regional and Country Analysis
8. Asia-Pacific Myopia and Presbyopia Treatment Market
9. China Myopia and Presbyopia Treatment Market
10. India Myopia and Presbyopia Treatment Market
11. Japan Myopia and Presbyopia Treatment Market
12. Australia Myopia and Presbyopia Treatment Market
13. Indonesia Myopia and Presbyopia Treatment Market
14. South Korea Myopia and Presbyopia Treatment Market
15. Western Europe Myopia and Presbyopia Treatment Market
16. UK Myopia and Presbyopia Treatment Market
17. Germany Myopia and Presbyopia Treatment Market
18. France Myopia and Presbyopia Treatment Market
19. Italy Myopia and Presbyopia Treatment Market
20. Spain Myopia and Presbyopia Treatment Market
21. Eastern Europe Myopia and Presbyopia Treatment Market
22. Russia Myopia and Presbyopia Treatment Market
23. North America Myopia and Presbyopia Treatment Market
24. USA Myopia and Presbyopia Treatment Market
25. Canada Myopia and Presbyopia Treatment Market
26. South America Myopia and Presbyopia Treatment Market
27. Brazil Myopia and Presbyopia Treatment Market
28. Middle East Myopia and Presbyopia Treatment Market
29. Africa Myopia and Presbyopia Treatment Market
30. Myopia and Presbyopia Treatment Market Competitive Landscape and Company Profiles
31. Myopia and Presbyopia Treatment Market Other Major and Innovative Companies
35. Myopia and Presbyopia Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Myopia and Presbyopia Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on myopia and presbyopia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for myopia and presbyopia treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myopia and presbyopia treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Disease Type: Myopia; Presbyopia2) by Myopia Treatment Type: Corrective; Surgical; Drugs
3) by Presbyopia Treatment Type: Prescription Lenses; Contact Lenses; Intraocular Lenses; Refractive Surgery
Subsegments:
1) by Myopia: Eyeglasses and Contact Lenses; Refractive Surgery; Pharmacological Treatments; Orthokeratology2) by Presbyopia: Multifocal Eyeglasses; Bifocal Contact Lenses; Presbyopia-Correcting Surgery; Pharmacological Treatments
Key Companies Mentioned: ALCON Inc.; Bausch & Lomb Incorporated; Carl Zeiss AG; Essilor Ltd.; Hagg Striet UK Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Myopia and Presbyopia Treatment market report include:- ALCON Inc.
- Bausch & Lomb Incorporated
- Carl Zeiss AG
- Essilor Ltd.
- Hagg Striet UK Ltd.
- Johnson & Johnson Vision Inc.
- Nidek Corporation
- Topcon Corporation
- Zimmer Ophthalmic Systems AG
- AbbVie Inc.
- Orasis Pharmaceuticals Ltd.
- Regeneron Pharmaceuticals Inc.
- Sydnexis Inc.
- The Cooper Companies Inc.
- Staar Surgical Co.
- Eyenovia Inc.
- Allergan PLC
- Hoya Corporation
- Novartis AG
- Menicon Co. Ltd.
- CooperVision Inc.
- Visioneering Technologies Inc.
- AcuFocus Inc.
- Ocular Therapeutix Inc.
- SightGlass Vision Inc.
- Presbia PLC
- Ophthotech Corporation
- OphthaliX Inc.
- LensGen Inc.
- Lightico Ltd.
- RxSight Inc.
- Perfect Lens LLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 22.7 Billion |
| Forecasted Market Value ( USD | $ 31.43 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 33 |
